WilliamG.WierdaMD

Oncology • Houston, TX

Hematologic Oncology

Physician

Join to view full profile

Dr. Wierda is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Wierda's full profile

Already have an account?

Office
1515 Holcombe Blvd
Houston, TX 77030
Phone+1 713-792-3753

Education & Training

University of California (San Diego) Medical CenterFellowship, Hematology and Medical Oncology, 1996 - 1999
Duke University HospitalResidency, Internal Medicine, 1993 - 1996
Chicago Medical School at Rosalind Franklin University of Medicine and ScienceClass of 1993

Certifications & Licensure

FL State Medical License 2021 - Present
CA State Medical License 1996 - 2025
TX State Medical License 2002 - 2025
OK State Medical License 2020 - 2021
NC State Medical License 1993 - 1999
American Board of Internal Medicine Medical Oncology

Clinical Trials

FCM-R (Fludarabine, Cyclophosphamide, Mitoxantrone, Rituximab) in Previously Untreated Patients With Chronic Lymphocytic Leukemia (CLL) < 70 Years Start of enrollment: 2005 Mar 14
Completed
Phase 2
Oxaliplatin, Fludarabine, Cytarabine and Rituximab in Richter's Syndrome, Refractory CLL and PLL Start of enrollment: 2004 Nov 01
Completed
Phase 1, Phase 2
CFAR Study in Patients With Chronic Lymphocytic Leukemia Start of enrollment: 2005 Jun 01
Completed
Phase 2
Multi-center Trial of Revlimid® and Rituximab, for First-Line Treatment of Chronic Lymphocytic Leukemia (CLL) Start of enrollment: 2008 Feb 01
Unknown status
Phase 2
8-Chloro-Adenosine in Chronic Lymphocytic Leukemia Start of enrollment: 2008 Jun 01
Completed
Phase 1
Identifying Prognostic Factors in Frontline FCR for Patients With Chronic Lymphocytic Leukemia (CLL) Start of enrollment: 2008 Aug 13
Completed
Phase 2
A Phase I Trial of Autologous CLL B Cells Transduced to Express Chimeric CD154 (ISF35) Start of enrollment: 2006 Jun 01
Completed
Phase 1
A Phase I Extension Trial of Repeated Infusions of ISF35 Start of enrollment: 2007 May 01
Completed
Phase 1
Cyclophosphamide, Fludarabine, Alemtuzumab, and Rituximab (CFAR) for Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL) Start of enrollment: 2002 Dec 01
Completed
Phase 2
Fludarabine, Bendamustine, and Rituximab (FBR) for Relapsed Chronic Lymphocytic Leukemia (CLL) Start of enrollment: 2010 Apr 19
Completed
Phase 1, Phase 2
Phase II Eltrombopag in Chronic Lymphocytic Leukemia (CLL) Start of enrollment: 2010 Nov 03
Completed
Phase 2
Ofatumumab for High-Risk Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL) Start of enrollment: 2011 Mar 01
Completed
Phase 2
Sapacitabine, Cyclophosphamide, Rituximab for Relapsed Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma (CLL/SLL) With Deletion (11q22-23) Start of enrollment: 2011 Aug 22
Terminated
Phase 2
Ofatumumab for Minimal Residual Disease (MRD) and Maintenance Therapy Start of enrollment: 2011 Jul 06
Active, not recruiting
Phase 2
Autologous ROR1R-CAR-T Cells for Chronic Lymphocytic Leukemia (CLL) Start of enrollment: 2015 Jan 01
Withdrawn
Phase 1
Study Evaluating the Efficacy and Safety of JCAR015 in Adult B-cell Acute Lymphoblastic Leukemia (B-ALL) Start of enrollment: 2015 Aug 21
Terminated
Phase 2
Study of Adoptive Cellular Therapy Using Autologous T Cells Transduced With Lentivirus to Express a CD33 Specific Chimeric Antigen Receptor in Patients With Relapsed or Refractory CD33-Positive Acute Myeloid Leukemia Start of enrollment: 2017 Aug 04
Terminated
Phase 1
CYC065 CDK Inhibitor and Venetoclax Study in Relapsed/Refractory CLL Start of enrollment: 2019 Jan 25
Completed
Phase 1
Trabectedin and Venetoclax in Treating Patients With Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma Resistant or Intolerant to a BTK Inhibitor Start of enrollment: 2019 Jun 18
Withdrawn
Phase 1
Acalabrutinib and Venetoclax With or Without Early Obinutuzumab for the Treatment of High Risk, Recurrent, or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma Start of enrollment: 2020 Jul 29
Recruiting
Phase 2
Study Evaluating Safety and Efficacy of JCAR017 in Subjects With Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL) Start of enrollment: 2017 Nov 27
Recruiting
Phase 1, Phase 2
Roles: Principal Investigator, Contact
Study to Evaluate Safety and Tolerability of XmAb13676 (Plamotamab) in Patients With CD20-expressing Hematologic Malignancies Start of enrollment: 2016 Oct 01
Active, not recruiting
Phase 1
Roles: Contact
Join now to see all

Publications & Presentations

PubMed

1140 citations
Use of CAR-Transduced Natural Killer Cells in CD19-Positive Lymphoid Tumors
Enli Liu, David Marin, Pinaki P. Banerjee, Homer A. Macapinlac, Philip A. Thompson
The New England Journal of Medicine. 2020-02-05
39 citations
A Phase I and Pharmacodynamic Study of AT9283, a Small-Molecule Inhibitor of Aurora Kinases in Patients With Relapsed/Refractory Leukemia or Myelofibrosis
James M. Foran, Farhad Ravandi, William G. Wierda, Guillermo Garcia-Manero, Srdan Verstovsek
Clinical Lymphoma, Myeloma & Leukemia. 2014-06-01
360 citations
Phase 1 study of the histone deacetylase inhibitor vorinostat (suberoylanilide hydroxamic acid [SAHA]) in patients with advanced leukemias and myelodysplastic syndromes
Guillermo Garcia-Manero, H. Yang, Carlos E. Bueso-Ramos, Alessandra Ferrajoli, Jorge E. Cortes
Blood. 2008-02-01

Journal Articles

A Pilot Study of Lower Doses of Ibrutinib in Patients with Chronic Lymphocytic Leukemia
Nitin Jain, Michael J Keating, Varsha Gandhi, William G Wierda, Blood
Evaluation of 230 Patients with relapsed/refractory Deletion 17p Chronic Lymphocytic Leukaemia Treated with Ibrutinib from 3 Clinical Trials
Steven Coutre, Richard R Furman, William G Wierda, Nyla A Heerema, Alvina D Chu, Jeffrey Jones, John C Byrd, British Journal of Haematology
Comprehensive Safety Analysis of Venetoclax Monotherapy for Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia
Jeffrey A Jones, William Wierda, Clinical Cancer Research

Abstracts/Posters

Venetoclax Added to Ibrutinib in High-Risk CLL Achieves a High Rate of Undetectable Minimal Residual Disease. [RTS1]
William G. Wierda, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
Constitutively Activated STAT3 Induces the Expression of Gli1 in Chronic Lymphocytic Leukemia Cells
William G. Wierda, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
The Early Achievement of Measurable Residual Disease Negativity in the Treatment of Adults with Philadelphia-Negative B-Cell Acute Lymphoblastic Leukemia Is a Strong P...
William G. Wierda, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
Constitutively Activated STAT3 Induces the Production of PTX3 That Contributes to the Induction of Bone Marrow Reticulin Fibrosis in Patient with CLL
William G. Wierda, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
Combined Ibrutinib and Venetoclax for First-Line Treatment for Patients with Chronic Lymphocytic Leukemia (CLL)
William G. Wierda, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
Cirmtuzumab, a ROR1 Targeted Mab, Reverses Cancer Stemness, and Its Combination with Ibrutinib Is Safe and Effective: Planned Analysis of the Cirll Phase 1/2 Trial for...
William G. Wierda, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
CG-806, a First-in-Class Pan-FLT3/Pan-BTK Inhibitor, Exhibits Broad Signaling Inhibition in Chronic Lymphocytic Leukemia Cells
William G. Wierda, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
Ongoing Results of a Phase 1B/2 Dose-Escalation and Cohort-Expansion Study of the Selective, Noncovalent, Reversible BrutonÍS Tyrosine Kinase Inhibitor, Vecabrutinib, ...
William G. Wierda, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
Outcomes of Ibrutinib (Ibr) Therapy in Ibr-Na¥ve Patients (pts) with Chronic Lymphocytic Leukemia (CLL) Progressing after Venetoclax (Ven)
William G. Wierda, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
Expansion of T Helper Cell Subsets in Chronic Lymphocytic Leukemia Cell Co-Cultures with Nurselike Cells
William G. Wierda, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
A Phase II Trial of Azacitidine (AZA) in Combination with Ruxolitinib (RUX) in Myelodysplastic Syndrome/Myeloproliferative Neoplasms (MDS/MPNs)
William G. Wierda, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
Determinants of Outcomes of FLT3mut Acute Myeloid Leukemia with First Salvage Therapy
William G. Wierda, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
A Phase I Study Combining CDK2/9 Inhibitor CYC065 with Venetoclax, a BCL2 Inhibitor, to Treat Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL)
William G. Wierda, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
Sinusoidal Obstructive Syndrome Among Pediatric and Adolescent and Young Adult Patients: Analysis of Pediatric EBMT Diagnostic and Severity Criteria at MD Anderson
William G. Wierda, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
MCL-1 and PKA/AMPK Axis Fuel Venetoclax Resistance in Lymphoid Cancers
William G. Wierda, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
Treatment Sequences and Outcomes of Patients with CLL Treated with Venetoclax and Other Novel Agents Post Introduction of Novel Therapies
William G. Wierda, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
Prognostic Factors for Progression in Patients (pts) with Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia (Ph+ALL) in Complete Molecular Response (CMR) w...
William G. Wierda, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
Cirmtuzumab, a ROR1 Targeted Mab, Reverses Cancer Stemness, and Its Combination with Ibrutinib Is Safe and Effective: Planned Analysis of the Cirll Phase 1/2 Trial for...
William G. Wierda, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
Ibrutinib, Fludarabine, Cyclophosphamide, and Obinutuzumab (iFCG) for First-Line Treatment of IGHV-Mutated CLL and without Del(17p)/Mutated TP53
William G. Wierda, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
Acalabrutinib Monotherapy in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia: 42-Month Follow-up of a Phase 2 Study
William G. Wierda, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
Updated Results from the Phase II Study of Hyper-CVAD in Sequential Combination with Blinatumomab in Newly Diagnosed Adults with B-Cell Acute Lymphoblastic Leukemia (B...
William G. Wierda, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
Treatment Sequences and Outcomes of Patients with CLL Treated with Venetoclax and Other Novel Agents Post Introduction of Novel Therapies
William G. Wierda, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
T Cell Determinants of Response and Resistance to PD-1 Blockade in RichterÍs Transformation
William G. Wierda, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
Ibrutinib (Ibr) Plus Venetoclax (Ven) for First-Line Treatment of Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL): Results from the MRD Cohort of t...
William G. Wierda, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
Treatment Discontinuation Patterns for Patients with CLL in the Real-World Settings: Results from a Multi-Center Study
William G. Wierda, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
Join now to see all

Lectures

Approaches to Personalized Treatment for CLL: Expert Guidance on Sequencing Therapy and Novel Agents
61st Annual American Society of Hematology Meeting - Orlando, FL - 12/7/2019
A Phase I Study Combining CDK2/9 Inhibitor CYC065 with Venetoclax, a BCL2 Inhibitor, to Treat Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL)
61st Annual American Society of Hematology Meeting - Orlando, FL - 12/7/2019
Combined Ibrutinib and Venetoclax in Patients with Treatment-Naïve High-Risk Chronic Lymphocytic Leukemia (CLL)
2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
A Prognostic Tool for the Identification of Patients with Early Stage Chronic Lymphocytic Leukemia at Risk of Progression
2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
Ibrutinib, Fludarabine, Cyclophosphamide, and Obinutuzumab (iFCG) for Firstline Treatment of Patients with CLL with Mutated IGHV and without TP53 Aberrations
2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
Association between Quality of Response and Outcome in Patients with Chronic Lymphocytic Leukemia Treated with Ibrutinib
2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
Chemoimmunotherapy with Inotuzumab Ozogamicin Combined with Mini-Hyper-CVD, with or without Blinatumomab, for Newly Diagnosed Older Patients with Philadelphia Chromoso...
2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
Phase 2 CAPTIVATE results of ibrutinib (ibr) plus venetoclax (ven) in first-line chronic lymphocytic leukemia (CLL).
2018 ASCO Annual Meeting - Chicago, Illinois - 06/3/2018
Join now to see all

Authored Content

Ibrutinib, Fludarabine, Cyclophosphamide, and Obinutuzumab (GA101) (iFCG) Treatment for First-Line Therapy of Patients with CLL with Mutated IGHV and Without Deletion 17pOctober 2017
The Combination of Quizartinib with Azacitidine or Low Dose Cytarabine Is Highly Active in Patients (Pts) with FLT3-ITD Mutated Myeloid Leukemias: Interim Report of a Phase I/II TrialOctober 2017

Press Mentions

New Directions in ALL, CML, and CLL TreatmentOctober 14th, 2024
BTK Inhibitor Active in Half of Patients with Richter TransformationSeptember 3rd, 2024
What’s New in Leukemia Research?May 29th, 2024
Join now to see all

Committees

Panel Member, NCCN Guidelines Insights: Non-Hodgkin's Lymphomas, Version 3.2016 2016 - 2016